These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9757136)

  • 21. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
    Zoete V; Michielin O; Karplus M
    J Mol Biol; 2002 Jan; 315(1):21-52. PubMed ID: 11771964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.
    Stoll V; Qin W; Stewart KD; Jakob C; Park C; Walter K; Simmer RL; Helfrich R; Bussiere D; Kao J; Kempf D; Sham HL; Norbeck DW
    Bioorg Med Chem; 2002 Aug; 10(8):2803-6. PubMed ID: 12057670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
    Munshi S; Chen Z; Yan Y; Li Y; Olsen DB; Schock HB; Galvin BB; Dorsey B; Kuo LC
    Acta Crystallogr D Biol Crystallogr; 2000 Apr; 56(Pt 4):381-8. PubMed ID: 10739910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations.
    Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C
    J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation.
    Harte WE; Beveridge DL
    Methods Enzymol; 1994; 241():178-95. PubMed ID: 7854178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
    Joshi A; Véron JB; Unge J; Rosenquist Å; Wallberg H; Samuelsson B; Hallberg A; Larhed M
    J Med Chem; 2013 Nov; 56(22):8999-9007. PubMed ID: 24160253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
    Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
    J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.
    Ganguly AK; Alluri SS; Caroccia D; Biswas D; Wang CH; Kang E; Zhang Y; McPhail AT; Carroll SS; Burlein C; Munshi V; Orth P; Strickland C
    J Med Chem; 2011 Oct; 54(20):7176-83. PubMed ID: 21916489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
    Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
    Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-ray structures of retroviral proteases and their inhibitor-bound complexes.
    Ringe D
    Methods Enzymol; 1994; 241():157-77. PubMed ID: 7854176
    [No Abstract]   [Full Text] [Related]  

  • 33. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.
    Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D
    J Med Chem; 1994 Aug; 37(17):2664-77. PubMed ID: 8064795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
    Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
    J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
    Lu Y; Yang CY; Wang S
    J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.